AVEO Pharmaceuticals, Inc. (AVEO) Expected to Post Earnings of -$0.06 Per Share


Wall Street brokerages expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to post earnings per share (EPS) of ($0.06) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for AVEO Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.06). AVEO Pharmaceuticals posted earnings of ($0.08) per share in the same quarter last year, which would suggest a positive year over year growth rate of 25%. The company is expected to report its next earnings report on Wednesday, August 8th.


On average, analysts expect that AVEO Pharmaceuticals will report full-year earnings of ($0.27) per share for the current year, with EPS estimates ranging from ($0.31) to ($0.23). For the next financial year, analysts forecast that the business will report earnings of ($0.45) per share, with EPS estimates ranging from ($0.62) to ($0.16). Zacks’ earnings per share averages are a mean average based on a survey of analysts that cover AVEO Pharmaceuticals.

Get AVEO Pharmaceuticals alerts:

AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.98 million.


A number of brokerages have recently commented on AVEO. ValuEngine raised AVEO Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Zacks Investment Research raised AVEO Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, May 4th. Finally, BidaskClub downgraded AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $4.05.


NASDAQ:AVEO traded up $0.01 during trading hours on Friday, hitting $2.21. The company’s stock had a trading volume of 2,270,470 shares, compared to its average volume of 1,149,993. The firm has a market capitalization of $262.70 million, a PE ratio of -13.81 and a beta of 1.52. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of -0.36. AVEO Pharmaceuticals has a twelve month low of $0.63 and a twelve month high of $4.24.

In related news, major shareholder Ravi Viswanathan bought 70,873 shares of the business’s stock in a transaction that occurred on Tuesday, May 8th. The shares were bought at an average price of $2.13 per share, with a total value of $150,959.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Equity Opportunities Iv Growth bought 236,479 shares of the business’s stock in a transaction that occurred on Monday, May 21st. The shares were bought at an average cost of $2.13 per share, for a total transaction of $503,700.27. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 2,098,458 shares of company stock worth $4,701,711. 4.40% of the stock is owned by insiders.


Several large investors have recently made changes to their positions in the stock. Prosight Management LP purchased a new position in shares of AVEO Pharmaceuticals during the fourth quarter valued at approximately $2,951,000. Point72 Asset Management L.P. boosted its position in shares of AVEO Pharmaceuticals by 213.5% during the first quarter. Point72 Asset Management L.P. now owns 940,403 shares of the biopharmaceutical company’s stock valued at $2,727,000 after buying an additional 640,403 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of AVEO Pharmaceuticals by 6.5% during the fourth quarter. Geode Capital Management LLC now owns 667,956 shares of the biopharmaceutical company’s stock valued at $1,863,000 after buying an additional 40,616 shares during the last quarter. Emory University purchased a new position in shares of AVEO Pharmaceuticals during the fourth quarter valued at approximately $1,682,000. Finally, Armistice Capital LLC purchased a new position in shares of AVEO Pharmaceuticals during the fourth quarter valued at approximately $1,674,000. 50.31% of the stock is currently owned by institutional investors.


About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)